Brian A. Gordon

TL;DR: Tau deposition in the temporal lobe more closely tracked dementia status and was a better predictor of cognitive performance than Aβ deposition in any region of the brain, supporting models of AD where tau pathology closely tracks changes in brain function that are responsible for the onset of early symptoms in AD.

TL;DR: Serum NfL dynamics in serum predict disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer’s disease, which supports its potential utility as a clinically useful biomarker.

TL;DR: This study provides Class II evidence that plasma Aβ42/Aβ40 levels accurately determine amyloid PET status in cognitively normal research participants and could be used in prevention trials to screen for individuals likely to be amyloids PET-positive and at risk for Alzheimer disease dementia.

TL;DR: Stable isotope labeling and mass spectrometry approaches are developed to measure the kinetics of multiple isoforms and fragments of tau in the human central nervous system (CNS) and in human induced pluripotent stem cell-derived neurons, indicating a biological link between amyloid plaques and tau physiology.

TL;DR: Mutation carriers had elevations in Aβ deposition, reduced glucose metabolism, and cortical thinning which preceded the expected onset of dementia, suggesting differential regional and temporal vulnerabilities to Aβ, metabolic decline, and structural atrophy, which should be taken into account when using biomarkers in a clinical setting.